









Markets
/
Stocks
/
nasdaq-adma
/

ADMA Biologics Inc

ADMA

8.951USD

-0.299-3.23%

Market hours （ET）Quotes delayed by 15 min

41.66MMarket Cap

14.52P/E TTM



ADMA Biologics Inc

8.951

-0.299-3.23%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ADMA Biologics Inc

Currency: USD Updated: 2026-03-27

Key Insights

ADMA Biologics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.67.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADMA Biologics Inc's Score

Industry at a Glance

Industry Ranking

14 / 157

Overall Ranking

67 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

ADMA Biologics Inc Highlights

StrengthsRisks

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 97.58% year-on-year.

Fairly Valued

The company’s latest PE is 15.00, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 228.97M shares, increasing 0.04% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 3.19K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

23.500

Target Price

+183.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of ADMA Biologics Inc is 8.91, ranking 21 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 139.16M, representing a year-over-year increase of 18.39%, while its net profit experienced a year-over-year increase of 55.87%.

Score

Industry at a Glance

Previous score

8.91

Change



Financials

8.61

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.84

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ADMA Biologics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of ADMA Biologics Inc is 7.29, ranking 80 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 15.00, which is 794.09% below the recent high of 134.13 and 4312.71% above the recent low of -632.00.

Score

Industry at a Glance

Previous score

7.29

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of ADMA Biologics Inc is 8.00, ranking 57 out of 157 in the Pharmaceuticals industry. The average price target is 30.00, with a high of 32.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

23.500

Target Price

+183.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

ADMA Biologics Inc

ADMA

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of ADMA Biologics Inc is 7.13, ranking 36 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 15.20 and the support level at 5.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.95

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.415

Sell

RSI(14)

24.807

Sell

STOCH(KDJ)(9,3,3)

16.676

Neutral

ATR(14)

1.233

High Vlolatility

CCI(14)

-132.429

Sell

Williams %R

77.767

Sell

TRIX(12,20)

-1.139

Sell

StochRSI(14)

48.229

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

10.418

Sell

MA10

12.829

Sell

MA20

14.316

Sell

MA50

15.630

Sell

MA100

16.810

Sell

MA200

16.839

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of ADMA Biologics Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 97.85%, representing a quarter-over-quarter decrease of 1.63%. The largest institutional shareholder is The Vanguard, holding a total of 20.80M shares, representing 8.73% of shares outstanding, with 24.18% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

32.70M

-1.95%

The Vanguard Group, Inc.

Star Investors

20.92M

-1.82%

State Street Investment Management (US)

13.56M

+12.28%

Sachem Head Capital Management LP

8.96M

Invesco Advisers, Inc.

10.49M

+2.89%

Westfield Capital Management Company, L.P.

5.11M

+57176.83%

Capital Research Global Investors

3.25M

Geode Capital Management, L.L.C.

5.81M

-1.68%

American Century Investment Management, Inc.

4.70M

+1.84%

Dimensional Fund Advisors, L.P.

4.80M

+0.74%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ADMA Biologics Inc is 6.77, ranking 47 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.